
Private wealth manager Bernstein has previously predicted that the obesity market in the US could be worth up to DKK 500bn (USD 72bn) within ten years – and Zealand Pharma wants in.
”If you look around, a lot of the large companies are realizing that they should get into obesity treatments, but they don’t have a pipeline. In that respect, Zealand Pharma is a relatively interesting player to team up with for access,” CEO Adam Steensberg tells Danish financial daily Børsen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app